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PHOTODYNAMIC THERAPY USING LUCIFERASE NANOCONJUGATE AS A 
TREATMENT FOR COLON CANCER  
 
TAMARA KORITAROV  
ABSTRACT 
Photodynamic Therapy (PDT) has proven itself in previous studies to be a 
successful therapeutic treatment for surface tumors, but its effectiveness is limited to only 
shallow depths that allow for the penetration of light. This study demonstrates that we 
have improved upon the conventional method of PDT and have overcome the previous 
depth limitation by creating the light at the location of the tumor in situ. We conjugated a 
bioluminescent protein, Luciferase, to a semiconductor nanoparticle, TiO2, and with a 
cell specific antibody, anti-EGFR monoclonal antibody C225. The nanoconjugate, 
TiDoL-C225, was then activated by ATP and Luciferin in a reaction that creates reactive 
oxygen species (ROS) and induces apoptosis in the tumor cells. We created the optimal 
nanoconjugate synthesis protocol to make TiDoL and TiDoL-C225 for use in the PDT 
treatment.  The TiDoL-C225 nanoconjugate is able to bind specifically to colon caner 
cells as the C225 antibody recognizes EGFR expressed at the surface of the cells, and 
further, when activated it will react only with the tumor cells. The optimal cell staining 
protocols were developed to visualize the treatment process and later analyze with the 
laser confocal microscope. The TiDoL nanoconjugate was found to only be operational 
and effective at killing tumor cells after being activated by Luciferin and ATP, which 
then enhances the control we have over the therapy. The TiDoL-C225 nanoconjugate 
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increases the efficacy of binding to tumor cells and the speed of the reaction in the cells 
to begin apoptosis, even in lower concentrations when compared to the free TiDoL 
nanoconjugate. Finally, our PDT technique allowed us to monitor the tumor cells as they 
begin to undergo apoptosis in less than five minutes after the Luciferin was added to 
activate the reaction. The advantage of our method of PDT with the TiDoL-C225 
nanoconjugate is that it can be used for early detection as well as developed into an 
effective treatment for cancers in all depths of tissue.  
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INTRODUCTION 
Photodynamic Therapy (PDT) 
 Photodynamic therapy (PDT) is an emergent technology used for the non-invasive 
treatment of malignant tumors, along with some viruses and diseases (Zhao et al., 2013). 
In PDT, light energy is converted into chemical energy that is used to create a highly 
reactive oxygen species (ROS) that have a cytotoxic effect on cell metabolism, and cause 
irreversible damage leading to the cell’s death (Zhao et al., 2013).  PDT aims to damage 
tumor cells and not cause damage to healthy cells that surround the tumor tissue (Zheng 
et al., 2012). However, PDT critically depends on the possibility of delivering light in the 
vicinity of the tumor. Light energy is needed to activate the photosensitizers in PDT, and 
the wavelength of light will clinically limit the depth of tissue that can be penetrated (Hsu 
et al., 2013).  
 In an effort to expand the effectiveness of PDT beyond that of surface tumors, 
scientists are working to develop new methods of PDT.  In the original PDT method the 
non-toxic dye photosensitizers were activated by visible light in vitro to attack and kill 
microorganisms such as bacteria, yeast, fungi, and viruses (Huang, Dai, & Hamblin, 
2010). The small penetration depth of light in the body is what limits the tumors than can 
be treated to ones that are at most within one centimeter of the light source (Wang, Chen, 
& Liu, 2013). This eliminates the possibility to treat deep tissue tumors with the classical 
method of PDT. Now, researchers are trying to address this issue by developing a new 
form of PDT with targeted light energy used with a variety of photosensitizer molecules 
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to create ROS that would go on to destroy tumor cells even deeper in the tissue 
(Macdonald & Dougherty, 2001). 
PDT methods depend on the use of direct light or invasive techniques, such as 
guided fiber optics, to get light near the tumor to react with the many photosensitizing 
agents that are currently approved for use in therapy to treat tumors (Schipper, Patel, & 
Gambhir, 2006). Newer PDT methods are trying to incorporate a biotechnology element 
that will be used to penetrate deeper and to try to reach tumors that are not near the 
surface. The new approach shifts from bringing light to the tumor to using 
bioluminescence reactions to create light within the tumor region. This means that the 
light will be created in situ by using light generating proteins such as Firefly Luciferase 
(fLUC) that are activated by highly energetic molecules in the process called 
bioluminescence (Schipper, Patel, & Gambhir, 2006). Firefly Luciferase can catalyze a 
reaction where D-Luciferin in the presence of magnesium and oxygen ions, and 
adenosine triphosphate (ATP) react to form light as a product (see Figure 1) (Zhao et al., 
2013). The D-Luciferin is however cytotoxic if not combined with a carrier such as the 
lipid microcapsules that have been used successfully in bioluminescent reactions to 
prevent tumor cells from proliferating (Zhao et al., 2013). Another new method for PDT 
is to use murine neural stem cells (NSCs) and rat umbilical cord matrix-derived stem 
cells (RUCMSCs) with the plasmid gene for gaussia Luciferase (gLUC) to engineer cells 
that will secrete the luciferase for in vivo PDT (Shrestha et al., 2012).  These advances in 
PDT may allow for its use as an effective treatment for deeper tissue tumors.  
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Figure 1. Bioluminescence. An illustration of the activation of a photosensitizer, 
Luciferin, with ATP, Magnesium and Oxygen ions via Firefly Luciferase to produce light 
and reactive oxygen species formation that results in bioluminescence. (Figure taken 
from Zhao et al., 2013). 
 
Adenosine Triphosphate (ATP) 
 One of the highly energetic molecules used in living organisms as an activator of 
bioluminescence is ATP, and in fireflies ATP is used to activate the Luciferin-Luciferase 
system and produce the green light that causes their abdomen to glow (Widder, 2010). 
Coincidentally, it has been found recently that cancer cells release 100-fold excess of 
extracellular ATP in the area of a tumor (Stagg & Smyth, 2010). The elevated ATP 
around tumor cells can be used as a targeting mechanism that will initiate a 
bioluminescence reaction of photoactive molecules only in the area of the tumor.  
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PDT with Nanoconjugates 
 We further developed this idea into a new and different approach to PDT. We will 
begin by conjugating the light source to the photosensitizer to create a single molecule 
that will eliminate the primary restriction of conventional PDT which is an external light 
source being able to reach the tumor site. This conjugated molecule will be made up of 
TiO2, a photosensitive nanoparticle capable of generating ROS after a bioluminescence 
reaction is initiated, and a Luciferase protein, the bioluminescent protein in fireflies, and 
importantly these two components are linked with Dopac, a conductive linker that is a 
metabolic precursor to the neurotransmitter Dopamine. TiO2 and other metal oxide 
nanoparticles have a high degree of surface curvature formed by distorted crystalline 
lattices composed of extremely reactive under-coordinated surface metal atoms (Rajh et 
al., 2002). The sites on the TiO2 nanoparticle’s curved surface exhibit a high affinity for 
oxygen-containing ligands, and as a result, can be electronically coupled to oxygen rich 
small molecules such as enediols or catechols, and in our coupling reaction we will use 
Dopac (Rajh et al., 2002). Upon functionalization with these Dopac molecules, the 
optical properties of the newly conjugated structure are enhanced to absorption in the 
visible and near-infrared (NIR) region of the light spectrum and its charge separation and 
chemical reactivity are improved (Rozhkova et al., 2009). This strong interaction can be 
used as a way to link groups and attach a variety of biomolecules to the surface of the 
metal oxide, and will enhance the binding of Luciferase to the TiO2-Dopac 
nanoconjugate (Rajh et al., 2002). Integrative composites of this type synergistically 
combine the physical robustness and photochemical reactivity of the nanoscale metal 
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oxides with the biological “lock and key” recognition capabilities of the biomolecules 
such as antibodies (Rajh et al., 2011). We will synthesize and characterize a 
nanoconjugate composed of TiO2 nanocrystals of about 5 nm in diameter that are 
covalently linked to biologically active targeting ligands, such as monoclonal antibodies 
(or peptides), and luciferase protein (Figure 2). 
 
Titanium Dioxide Toxicity to Cells 
 The toxicity of TiO2 nanoparticles towards the human organism is a concern. In a 
recent study by Setyawati et al. (2013), it was shown that TiO2 nanomaterials of 23.5 nm 
caused endothelial cell leakiness in concentrations of 10 uM or greater, however when 
Figure 2. TiDoL Nanoconjugate. Conjugation and activation of bioluminescence 
reaction with Luciferase and Luciferin to create ROS and kill the targeted cancer cell.  
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micro sized TiO2 of 680 nm was used at the same concentrations and exposure time it did 
not cause any disruption to the endothelial cells. Setyawati et al. (2013) believe that the 
smaller 23.5 nm TiO2 nanomaterials can migrate into endothelial cell junctions and 
disrupt the VE-Cadherin complexes to cause the endothelial cell leakiness or in vivo 
vascular leakiness. The TiO2 nanoconjugates that we make will have the TiO2 
nanoparticles functionalized with Dopac molecules at 20 nm and then to Luciferase 
protein, which is approximately 12 nm, in addition to the targeting antibody that 
altogether the nanoconjugate is larger than 23.5 nm (Conti, Franks, & Brick, 1996). 
Importantly, the surface active sites that are involved in the interference with VE-
Cadherin are altered by surface functionalization and the presence of corona proteins, 
resulting in modulated reactivity of TiO2 that is governed by reactivity of Dopac and 
corona proteins so that the nanoconjugate should not be able to interfere with the VE-
Cadherin complexes (Rajh et al., 2002).  
Selective Targeting with Antibodies 
The targeting of monoclonal antibodies is employed for site selective recognition 
and binding to particular cancer cells, while Luciferase provides a visible light trigger for 
the conjugate to participate in photo-activated apoptosis through the production of ROS. 
The nanoparticle bound Luciferase catalyzes the reaction of Luciferin with energetically 
rich ATP, present in enhanced extracellular levels in areas near the tumor to produce light 
in situ (Stagg & Smyth, 2010). This light in turn activates the nanoconjugates to generate 
a large enough quantity of ROS that ultimately cause the targeted cells to undergo 
apoptosis (Rozhkova et al., 2009). This therapy has no effect on the healthy cells in the 
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nearby environment due to selective binding to tumor cells, and does not bind the 
nanoparticles modified with cancer-targeting monoclonal antibodies because the 
surrounding healthy tissue has a substantially lower local concentrations of ATP in the 
extracellular region of sub-micromoles/L compared to the excess ATP in the 100s of 
micromoles/L in the cancerous regions (Stagg & Smyth, 2010). We will use extracellular 
ATP around the tumor cells to power Luciferase protein attached to nanoparticles of TiO2 
capable of recognizing cancerous cells by the selective monoclonal antibody binding to 
the receptors that are uniquely overexpressed on the tumor cell surface. The light created 
in situ from the Luciferase will then activate the semiconductor TiO2 nanoparticles 
attached to them and produce photoactive species resulting in efficient ROS production 
and inducing programmed cell death (Lee & Kopelman, 2011). This approach is a 
breakthrough in conventional PDT technology as it eliminates the major limitation of the 
technology by creating a nanoconjugate that can be activated near tumor cells and cause 
them to undergo controlled cell death. The advantage of this approach is that it can be 
used for early detection as well as for early treatment of cancers. Additionally, light 
created in situ can be utilized to power a variety of light driven devices deep in the tissue.  
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SPECIFIC AIMS 
 
PDT has proven itself in previous studies to be a successful therapeutic treatment 
for surface tumors. The only limitation for PDT has been its effectiveness at only shallow 
depths that allow for the penetration of light. New and original techniques are required to 
reach deeper tumors with light. Some such techniques have started experimentation with 
bioluminescence in tumor regions. 
This project aims to combine bioluminescence of the cancerous cell’s 
overproduced ATP with the firefly Luciferase protein attached to a semiconductor 
nanoparticle that is able to recognize the cancer cells by binding to specific receptors 
uniquely expressed on the cancer cells.  This selective binding will allow for PDT 
bioluminescence to work, selectively causing apoptosis of the cancer cells in tumors at 
any depth of tissue. This approach can break through the previous limitations of PDT by 
delivering light in vivo to deeper tissues. The project’s success can be further 
implemented in not only the treatment of tumors, but early detection of deep tissue 
tumors that may not show symptoms until they are fairly developed, and hopefully a cure 
for cancer.  
We hypothesize that PDT using bioluminescence from firefly Luciferase protein 
will be successful in causing selective apoptosis of HCT116 colon cancer cells in any 
depth of tissue. We hope to further the methods of PDT and pave the way for a reliable 
treatment and future cure for cancer.  
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METHODS 
 
  
Zetasizer 
 The Zetasizer (Malvern Zetasizer Nano-ZS, Malvern, UK) was used to measure 
the zeta potential of TiO2 samples (Appendix A). Zeta potential is used to quantify the 
magnitude of the electrical charge. The samples were varied by amount of Tiron and 
Dopac added and the process of filtration. We hypothesized that the Dopac replaces Tiron 
on the nanoparticle surface due to lower hydrophylicity. Samples were placed in a cell 
and then in the Zetasizer. This instrument generates a graph indicating the peak zeta 
potential resulted after running a sample. The more DOPAC added to the nanoparticle 
solutions generally decreased the negativity of the zeta value, in agreement with its single 
negative charge compared to Tiron having a double negative charge. 
Spectrophotometer 
 The spectrophotometer (Varian Cary 50 Scan UV-Visible Spectrophotometer, 
Palo Alto, CA) is used to detect diffusive and specular reflectance measurements 
(Appendix B). The sample to be tested is contained in a cell that is then placed into the 
sample compartment of the instrument and covered. Data is collected by the computer 
program for the instrument and formatted into a graph with x-axis of wavelength in nm 
and with the y-axis in absorption. The absorption at wavelength of 410 nm was of 
interest, and used as a reference point when comparing samples. 
Confocal Laser Microscope 
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 The Zeiss LSM 510 confocal microscope (Carl Zeiss, Oberkochen, Germany) was 
used to image cell cultures in three dimensions (Appendix C). The confocal microscope 
allows for the cell cultures to be imaged with function-specific fluorescent dyes and 
viewed under the microscope as they fluoresce with AxioVision software. Cell cultures 
are stained with multiple dyes. Each dye is designed to specifically label cell organelles; 
therefore, each organelle of the cell can be viewed simultaneously by deconvoluting each 
color. The microscope can be configured as single track or multi-track. Single-track 
configuration is mainly used for single dye labeling, or with multiple dyes that are 
excited by different wavelengths. Multi-track is used for double or triple dye labeling, 
with sequential scanning. Multi-track reduces dye crosstalk, because when one track is 
active only one detector and one laser are on. The confocal microscope has a program 
that allows for creation of a z-stack with optical slices to image a cell culture in 3-D. Cell 
cultures can also be viewed in a time series, enabling visualization of the cell cultures in 
real time. The scan speed of the microscope can be adjusted, with slower scan speeds 
producing superior images. Frame averaging can reduce noise and produce a higher 
resolution image. The cell cultures can also be observed with regular light recorded by 
the camera. This mode is used when laser intensity modulates imaging parameters. 
Camera for Optical Inverted Microscope 
 The optical upright microscope (VWR VistaVision, Radnor, PA) was used to 
examine the cell cultures, and monitor progress daily (Appendix D). The camera 
attachment (Carl Zeiss AxioCam CM1, Oberkochen, Germany) was used to take 
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photographs with the Axio Imager software to document photos of the cell cultures. Cells 
were counted when view under the microscope in the cell counting chamber. 
Cell Culture 
  Work with cells was conducted in a Biosafety Level 2 (BSL 2) Laboratory in a 
biosafety cabinet with HEPA filtration (LabCONCO Purifier Class II Biosafety Cabinet, 
Kansas City, MO), designed specifically for handling materials compliant with BSL 2 
regulations (Appendix E). The biosafety cabinet provides the operator and environment 
protection from hazardous particulates through the control of airflow and HEPA 
filtration. The following are the procedures for working with the biosafety cabinet. The 
biosafety cabinet should be operated with required personal protective equipment, and 
appropriate clothing and footwear for the BSL 2 environment. Before starting work in the 
biosafety cabinet, the blower should be turned on, the UV light should be on for 15 
minutes and then turned off before beginning work and the regular light should be turned 
on. Open the sash. The cabinet should be disinfected with 70% ethanol solution (Sigma-
Aldrich, St. Louis, MO) while the blower is on.  Any containers should be disinfected 
with 70% ethanol solution before being placed in the biosafety cabinet to minimize any 
contamination inside the cabinet. Maintain the sterility of gloves by periodically spraying 
them with 70% ethanol. When work in the biosafety cabinet is completed, remove all 
items from the cabinet, and spray the working surface with 70% ethanol and wipe it down 
with a paper towel. Discard any waste including the paper towel in a biohazard container. 
Close the sash and turn on the UV lights for at least 15 minutes. Then before leaving the 
lab turn off the UV lights and the blower. 
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When the cell cultures were not being worked with, the cells were stored in a CO2 
incubator (Sanyo CO2 Incubator, San Diego, CA) (Appendix F). The incubator was 
programmed to maintain environmental conditions that are optimal for cell culture 
growth; the operating conditions are 37 degrees C temperature, 95% humidity, and 5% 
CO2 level. Cell cultures were periodically observed under the inverted microscope to 
ensure the adequate speed of cell culture growth and the lack of bacterial contamination. 
Photographs taken of the cells under the microscope were documented. Cell cultures 
were grown in T75 vented flasks filled with cell growth medium. The cell line used in 
this experiment was HCT116 cells (University of Chicago, Chicago, IL) that are human 
colon cancer cells with an overexpression of epidermal growth factor (EGF) receptors 
(ATCC, 2013). The HCT116 cells are epithelial cells, and therefore adherent. HCT116 
cells are kept in a growth medium with the base medium being McCoy’s 5a Medium 
Modified (Gibco, Grand Island, NY), with fetal bovine serum (Gibco, Grand Island, NY) 
added to a final concentration of 10%, and penicillin-streptomycin (Sigma-Aldrich, St. 
Louis, MO) added to a final concentration of 5%.  
 All working surfaces were disinfected with 70% ethanol before and after use. 
Personal protective equipment used includes safety glasses, laboratory coat, and chemical 
resistant nitrile gloves. All materials that come into contact with cell culture work were 
disposed of in the appropriate biohazard containers. 
Subculturing/Splitting the Cells 
 HCT116 cell cultures should be subcultured when they are grown at 70%-90% 
confluence. Cell subculture should be performed only inside the biosafety cabinet in 
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order to ensure the sterility of the cell culture and to avoid potential contamination. The 
culture medium should be removed from the T75 flask with a Pasteur pipette and 
vacuum. When removing culture medium, tip the flask vertically and take care not to 
disturb the cells adhered to the bottom and not to touch the cells with the tip of the 
pipette. The flask should then be washed with 5 mL of Hank’s Balanced Salt Solution 
(HBSS). HBSS (Sigma-Aldrich, St. Louis, MO) is then removed with Pasteur pipette and 
discarded from the flask the same way as the growth medium. Then, 5 mL of 1% 
Trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO) is added to the flask to dissolve 
the extracellular matrix and detach the cells from the surface. Then, the flask should be 
put in the incubator for approximately 10 minutes. The flask should be taken out after 10 
minutes and checked to see if the cell layer has detached itself from the bottom of the 
flask and that the cells are dispersed. Add 5 mL of HCT116 growth medium to the cells 
to stop the effect of Trypsin. Gently pipette the cell suspension into aliquots to be 
centrifuged. The cells should be spun down for 5 minutes at 1000 rpm. After the cells 
have spun down and formed a pellet, remove any of the supernatant. Gently resuspend 
cells in 3 mL of warmed growth medium and add desired amount of cell suspension to 
the new labeled T75 flasks filled with 15 mL warmed cell growth medium. Return the 
flasks to the incubator. Growth medium should be replaced every two to three days.  
 When conducting experiments, cells can be added to 4-well or 8-well plates. 
When cells are being subcultured, at the step when they are resuspended after 
centrifugation, a drop of cell suspension can be added to a cell counting chamber slide. 
The cells can be observed in the chamber under the microscope and counted. The cell 
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count can then be extrapolated to find the concentration of cells per milliliter of solution. 
This measurement is necessary to calculate a desired concentration of cells per well. The 
desired amount can be added to wells containing cell growth medium and returned to the 
incubator.  
Binding of Antibodies to HCT116 Cells With C225 Antibody or Iressa 
 HCT116 cells were used in two 6-well collagen I coated plates with a 
concentration of 300,000 cells/well/2 mL of 10% serum growth medium. The cells would 
be pre-treated with C225 antibody (40 ug/mL) or Iressa (500ng/mL) (Gefitinib, 
AstraZenca, Macclesfield, UK) for two hours. The experiment agonist is varied amounts 
of Epidermal Growth Factor (EGF) (0.5, 1, 5, and 10 ng/mL) (Cell Signaling 
Technologies, Danvers, MA) for five minutes. Carry out the experiment as diagramed 
below.  
Plate #1   
1: Control- nothing added 2: EGF 0.5 ng/mL 3: EGF 1.0 ng/mL 
4: EGF 5.0 ng/mL 5: EGF 10.0 ng/mL 6: Control- nothing added  
  
Plate #2   
7: C225 40 ng/mL + 
EGF 0.5 ng/mL 
8: C225 40 ng/mL + 
EGF 1.0 ng/mL 
9: C225 40 ng/mL + 
EGF 5.0 ng/mL 
10: C225 40 ng/mL + 
EGF 10.0 ng/mL 
11: Iressa + 
EGF 10.0 ng/mL 
12: C225 40 ng/mL 
 
 
 
Table 1. HCT116 Experiment Treatment of Wells. Set up of the two HCT116 6-
well plates with EGF only or C225 and EGF. 
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Retrieve Protein After an Experiment  
To retrieve protein from HCT116 cell cultures in the experiment, first remove 
cellular growth medium from each well of the cell plates at the specified time point. 
Wash the cells in each well with 2 mL HBSS, and carefully remove the HBSS with a 
Pasteur pipette and vacuum as to not disturb the cell cultures. Next, add 2 mL of growth 
medium to each well. Place the cell plates on ice. Use a cell scraper to scrape the 
adherent cells off of the bottom of the well in the plate until they become a goopy mass. 
Repeat this for each well and rinse the cell scraper in water before moving on to the next 
well to avoid any sample contamination. Next, use a pipette to transfer the cells from 
each well into an individual labeled 1 mL tube. Boil the tubes for four minutes in a 100 
degree C water bath to denature the proteins. Incubate the tubes at room temperature for a 
few minutes. Then place the tubes in the -80 degree C freezer until ready to use. 
Protein Assay 
 Remove protein samples from freezer and thaw them at room temperature. Then, 
once thawed, boil the samples for four minutes in a 100 degree C water bath. Next, 
centrifuge (Eppendorf Centrifuge 5424, Hamburg, Germany) the samples at 14,000 rpm 
for five minutes. Once the samples have finished centrifuging, take out 5 uL of the 
sample (1-12) for protein estimation as a duplicate or triplicate and place in separate 
labeled 1 mL tubes. The number of tubes from the samples is 12, so for a triplicate there 
would be a total of 12 x 3 = 36 tubes, or for a duplicate there would be a total of 12 x 2 = 
24 tubes. Use a Bovine Serum Albumin (BSA) (Sigma-Aldrich, St. Louis, MO) standard 
stock solution of 1 mg/mL concentration. To make a standard curve for the duplicates or 
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triplicates use: 0, 1.5, 3, 4, 10, 20, 40, 60, 80, 100, 125, and 150 ug of BSA standard 
stock solution in separate labeled 1 mL tubes. The total number of tubes for the BSA 
standard curve will be 12 x 3 = 36 for the triplicate or 12 x 2 = 24 for the duplicate. Next, 
add 125 uL of RC Reagent I to each of the protein sample and the BSA standard tubes. 
Close the tubes and vortex them so that there is no sediment. Incubate the tubes for one 
minute at room temperature. Next, add 125 uL of RC Reagent II into each tube of the 
protein samples and the BSA standard tubes. Close the tubes and vortex them so there is 
no sediment. Then keep the tubes at 4 degrees C for overnight or at -20 degrees C for one 
hour. After time has passed, remove the tubes from the refrigerator or freezer. Centrifuge 
the tubes at 14,000 rpm for five minutes. Decant the supernatant in each tube, and keep 
the tubes upside down for 10 minutes to dry. Then, add 125 uL of Reagent A’ to each of 
the protein sample and BSA standard tubes. Reagent A’ is made by using 5 uL of DC 
Reagent S for each 250 uL of DC Reagent A (5:250 ratio). Close the tubes and vortex 
them until the precipitant has completely dissolved. Add 1 mL of DC Reagent B to each 
of the protein sample and BSA standard tubes. Close the tubes and vortex them 
immediately. Incubate the tubes for 15 minutes at room temperature. Once again vortex 
all of the tubes. Take out 200 uL from each of the tubes and pipette them into a 
designated well on a 96 well plate. Measure Optical Density (OD) at 750 nm on the plate 
reader. The BSA (0 uL) standard tube without protein was used to set a baseline for the 
spectrophotometer. The remaining BSA standard tubes were used as a reference for 
determining the protein concentration of the collected unknown samples. The results 
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were recorded in a Microsoft Excel spreadsheet, and the protein concentrations in the 
unknown collected protein samples were determined.  
Western Blot Analysis 
 Making the gels: Protein assays from experiment with HCT116 cells were 
collected to be able to calculate the amount of protein in each sample. The gels will be set 
up to use these protein concentrations in a Western Blot. The protein samples were boiled 
for four minutes in a 100 degree C water bath. Then, protein samples were centrifuged at 
14,000 rpm for five minutes. From the previous protein assay calculations of protein 
density for each sample, calculate how much 2X Laemmli sample buffer (Sigma-Aldrich, 
St. Louis, MO) to add to each protein sample. Set up the gel running box (electrophoresis 
cell), and add a little of the 1X Gel running buffer to the bottom of the container. Then, 
take a mini pre-cast gel package and open it. The gels used were 10-well combo gels. 
Wash the gel with water to remove any bubbles, and then pat it dry. Label the gel. 
Position the gel in the gel running box and line up the grooves with the tray. Add some 
1X gel buffer to check for leaks. Fill the tray with 1X gel running buffer and let it spill 
over until the height of buffer is about 1 inch from the top of the running box edge. Use a 
pipette to add 7 uL of protein marker standard to one well. Use another pipette to add 40 
uL of each sample standardized to contain 100 ug of protein to their designated wells, 
using the plastic wall as a guide to slowly add protein to the well. Do not let the pipette 
go too deep in the well because it can puncture the gel. Repeat this process for each 
protein and their designated well. Add the gel running box lid and connect the wires to 
the voltage source. Red is positive, black is negative. Make the DC current on the 
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apparatus 100 volts. Once the apparatus is turned on, there should be small bubbles in the 
buffer that indicate that it is running. Let the gel run for 45 minutes to an hour until the 
proteins reach the bottom of the gel. Turn of the gel apparatus, disconnect the wires, and 
take off the lid. Dump out the buffer and remove the gel. 
 Transfer the membrane: Open the tray and remove the gel. Remove the plastic 
side of the gel and break open the seal. Cut the bottom of the gel and the top of the cones 
off. Place the gel in a dish filled with transfer buffer and remove it from the plastic side. 
Cut cardboard squares and sponges for the transfer cassettes. Cut the transfer membrane 
to be the size of the Western Blot gel boxes. Use 1X transfer buffer. Activate the transfer 
paper by soaking it in methanol for 30 seconds. Wash the transfer paper in transfer buffer 
after activating it. To make the transfer cassette, first put the black side on the bottom, 
then layer the thick sponge soaked in transfer buffer, then the paper soaked in transfer 
buffer and remove bubbles by pressing a pipette over the surface, then place the transfer 
membrane soaked in transfer buffer on top of the paper and remove bubbles, then place 
the gel over the membrane and remove bubbles, then add another soaked paper on top of 
the gel and remove bubbles, then place the thin sponge soaked in transfer buffer on top, 
and finally close the cassette with the gray side on top. Set up the transferring machine 
with the red (+) in the back and the black (-) in the front so the proteins will be 
transferred to the membrane because the machine carries a charge from negative to 
positive. Place the cassette in the transfer machine with the gray side facing forward. 
Connect the wires; hook the machine up to a water source and the output to the sink. Set 
the transfer machine current to 75 milliAmps and let it run overnight. 
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Each primary antibody used in Western blots has a specific protocol. Primary 
antibodies that were used with the HCT116 cell experiment were P-AKT, P-ErbB2 (P-
neu), P-ERK, and P-EGFR (Santa Cruz Biotechnology Inc., Dallas, TX). For example 
when P-EGFR was used, the conditions were as follows. First there is a blocking period 
of 1-2 hours at room temperature where the membrane is in 5% milk at pH 7.5. Then the 
primary antibody P-EGFR was added to 10 mL of 5% milk at a dilution of 1:200, and left 
overnight on a shaker at 4 degrees C. The next day the membranes were washed three 
times for six minutes each with Tris-Buffered Saline and Tween 20 (TBST) (Sigma-
Aldrich, St. Louis, MO). After washing, small labeled blot containers were filled with 10 
mL of 5% milk with a 1:3,000 dilution of the secondary antibody donkey anti goat, and 
the membranes were placed in them and left on a rocking plate for one hour at room 
temperature. After an hour, the membrane was removed from the blot container and 
washed four times for six minutes each time with TBST. Finally the membrane was 
sprayed with ECL (Sigma-Aldrich, St. Louis, MO), a developing solution, for 30 
seconds. The membrane was then transferred to a developing cassette, and place between 
two plastic transparencies. The cassette was taken to a dark room where the film was 
exposed for a variety of time periods and then the autoradiogram was developed. The 
autoradiogram was then labeled and interpreted for results. 
TiO2 Functionalization/Making TiDoL 
 From the 1 mg/mL stock solution comprised of 8.33 uM Luciferase (Sigma-
Aldrich, St. Louis, MO) take 250 uL of stock Luciferase and add to a 1 mL Eppendorf 
tube. Add 30 uL of already mixed 0.5 mL of 10 mg/mL Dopac (Sigma-Aldrich, St. Louis, 
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MO), 0.5 mL of 10 mg/mL 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) (Sigma-Aldrich, St. Louis, MO), and 0.5 mL of 10 mg/mL N-
Hydroxysuccinimide (NHS) (Sigma-Aldrich, St. Louis, MO) in a nitrogen box. Incubate 
the solution for two hours at room temperature in the nitrogen box. Then, dilute the 
solution to 0.5 mL and wash four times with Phosphate Buffered Saline (PBS) (Sigma-
Aldrich, St. Louis, MO) in the centrifuge purification system for six minutes at 13,500 
rpm. After the last wash leave 100-125 uL and add into 200 uL of 10 uM TiO2 (prepared 
at the Center for Nanoscale Materials following protocol described previously in 
Paunesku et al., 2003). A faint yellow color should appear when the new solution is 
made. This preparation leads to a final concentration of 6.2 uM Titanium Dioxide Dopac 
Luciferase or as we will refer to it, TiDoL, and an excess of 3.3 Luciferase per molecule 
of TiDoL. This TiDoL solution can be used both by itself, and in that case add 25 uL of 
Dopac, or the TiDoL can be further modified with an antibody such as C225. 
Making TiDoL-C225 
 Take 125 uL of 2 mg/mL corresponding to 13.3 uM C225 (Cetuximab/Erbitux, 
Eli Lilly, New York, NY) Anti-EGFR monoclonal antibody and add it to a 1 mL 
Eppendorf tube. Then add 30 uL of already mixed 0.5 mL of 10 mg/mL Dopac, 0.5 mL 
of 10 mg/mL EDC, and 0.5 mL of 10 mg/mL NHS in a nitrogen box. Incubate the 
solution for two hours at room temperature in the nitrogen box. Then, dilute the solution 
to 0.5 mL and wash 4x with Phosphate Buffered Saline (PBS) in the centrifuge 
purification system for six minutes at 13,500 rpm. After the final wash, the final volume 
should be approximately 125 uL of the C225 solution at a concentration of 13.3 uM. 
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Take 75 uL of the C225 solution and add it to 150 uL of 6.2 uM TiDoL. This preparation 
makes a final TiDoL-C225 solution with a concentration of 4.15 uM with a 0.28 uM 
concentration of free C225, which is approximately 5% excess.  
Treating Cells with Nanoparticles 
 Cell cultures grown in 4-well or 8-well plates were treated with nanoparticles and 
observed. For 8-well plates final concentrations of solution were 300 uL, and for 4-well 
plates amounts were doubled to a final concentration of 600 uL. Cell cultures were 
treated with nanoparticles by adding TiO2, TiO2-Dopac, or the 620 nM TiDoL solution 
previously described. In other experiments cell cultures were treated by adding the                                                                                                                                                                                    
TiDoL-C225 solution in the concentration of 415 nm to the well.  
Cell Staining 
  Every cellular dye has a specific staining protocol for living cells. The majority 
of cell cultures in 4-well or 8-well plates were stained first by adding the cellular dye 
(Invitrogen, Life Technologies, Grand Island, NY) to growth medium in the well and left 
to incubate for a specific amount of time. After the allotted time, the dye and medium 
were removed from the well with a pipette. The wells were washed twice with growth 
medium, and then twice with HBSS. Some experiments required only one cellular dye, so 
they could be imaged after the washings were completed. However, if more than one 
cellular stain was required, after the washings the next cellular dye could be added to 
growth medium and the staining process repeated for each additional dye. Once cells 
were observed, the cell cultures were given fresh growth medium and returned to the 
incubator.  
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RESULTS 
  
OPTIMIZE TiO2-PROTEIN NANOCONJUGATE SOLUTION 
 An investigation was carried out to find the optimum synthetic parameters of the 
nanoconjugate that maximize the light output and hence the formation of reactive oxygen 
species (ROS) in vitro. It is necessary to synthesize and characterize the nanoconjugate in 
which TiO2 nanocrystals are covalently linked to biologically active targeting ligands and 
luciferase protein. Structure and function relationships were studied to understand how 
the attachment of the protein systems to the nanoparticle surface affects its generation 
and transport of light and ROS. This is important in creating a system that will be highly 
efficient. Binding of a protein or peptide to TiO2 can enable targeting of the hybrid TiO2-
protein nanoconjugate to the specific cell protein or organelle. In the simplest case 
luciferase and the targeting antibody were added to the surface of the nanoparticle as 
individual components. The number of each species and the ratio between them was 
varied, and the performance of the nanoconjugate was tested. Another approach of 
creating a chimera, by fusing the luciferase protein and targeting antibody, and attaching 
it to the surface of the nanoparticle as a single component proved unsuccessful (Kobatake 
et al., 1993).  
 This study focused on binding anti-EGFR monoclonal antibody, C225, to TiO2 
semiconducting nanoparticle as a cell-targeting agent. The aim for this TiO2-C225 
nanoconjugate was to bind to the surface or within the matrix of a target cell, where it can 
then initiate a series of redox reactions and alter cell functions.  
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HCT116 CELLS AND ANTIBODY WESTERN BLOTS 
 Western blots were made from proteins of HCT116 cells treated with C225 anti-
EGFR monoclonal antibody for two hours, and with various concentrations of the agonist 
EGF. The blots were probed with the following antibodies: P-AKT, P-ErbB2 (P-Neu), P-
ERK, and P-EGFR. With each antibody we probed with, we found that there was very 
good inhibition with C225 at various concentrations of EGF. The signal of the EGF at 
each concentration was always more pronounced than with the same concentration of 
EGF with C225 antibody (40 ug/mL).  
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Figure 3. Western Blots. Western blots of the HCT116 cell experiment with C225 
antibody and EGF agonist are shown in a compilation of images. The blots were 
probed with a number of antibodies including P-AKT, P-ErbB2 (P-Neu), P-ERK, and 
P-EGFR. All showed inhibition with 40 ug/mL C225 compared to the EGF only 
control of equal concentration. Starting from the left; Lane 1: protein marker standard, 
Lane 2: control, Lane 3: EGF 0.5 ng/mL, Lane 4: C225 + EGF 0.5 ng/mL, Lane 5: 
EGF 1 ng/mL, Lane 6: C225 + EGF 1 ng/mL, Lane 7: EGF 5 ng/mL, Lane 8: C225 + 
EGF 5 ng/mL, Lane 9: Iressa 500 ng/mL + EGF 10 ng/mL, Lane 10: C225 alone. 
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OPTIMIZE STAINING 
 Cellular staining procedure was optimized after following distributor instructions. 
Some cellular staining procedures needed to be altered depending on how visible they 
were under the confocal microscope. Our optimal staining procedures were determined 
by changing concentrations and incubation times until our desired stain was found. 
Wheat germ agglutinin (WGA) (Invitrogen, Grand Island, NY) was used for staining the 
cell membrane in a fluorescent green color (Alexa 488). WGA binds to N-
acetylglucosaminyl residues on the cellular membrane and sialic acid residues found on 
the surface of cell membranes (Molecular Probes Inc., 2009). WGA is also used as an 
indicator for the Golgi apparatus and nuclear core complexes (Molecular Probes Inc., 
2009). The staining procedure used for WGA is to add 75 uL of WGA to 250 uL of 
cellular growth medium and incubate the cell cultures for ten minutes. After incubation, 
the cells should be washed with cellular medium and then once with HBSS before 
imaging.  
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 Mitosox Red (Invitrogen, Grand Island, NY) was a cellular stain that was used to 
image the mitochondria. Mitosox Red is permeable through the cellular membrane and is 
rapidly oxidized by superoxide generated in the mitochondria but not by other ROS to 
produce a red fluorescence (Molecular Probes Inc., 2005). The staining procedure for 
Mitosox Red is to add 50 uL of Mitosox Red to 250 uL of cellular growth medium and 
incubate the cell cultures for ten minutes. After incubation, the cells should be washed 
with cellular medium and then once with HBSS before imaging. The red fluorescence 
Figure 4. WGA. Live HCT116 cells stained with WGA and viewed under the laser 
confocal microscope at 100x magnification. The cellular membrane and Golgi 
apparatus (indicated with arrows) are visible when stained. 
 
10 um 
WGA Transmitted Image 
Merged 
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with Mitosox Red was not precise enough for the study. We found that Mitotracker Red 
(Invitrogen, Grand Island, NY) was better at staining the mitochondria with red 
fluorescence, and this became our stain of choice. Mitotracker Red works differently than 
Mitosox Red. Mitotracker Red is a cationic dye that accumulates in the mitochondria, due 
to its positive charge it binds to sulfhydryl groups (Molecular Probes Inc., 2008). The 
staining procedure for Mitotracker Red is to add 50 uL of Mitotracker Red to 250 uL of 
cellular growth medium and incubate the cell cultures for 30 minutes. After incubation, 
the cells should be washed with cellular medium and then once with HBSS before 
imaging. 
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The nucleus of the cellular cultures was stained with Hoechst (Invitrogen, Grand 
Island, NY). Hoechst binds to the minor groove of DNA, and it can bind to all nucleic 
acids with a preference for sequences rich in adenine and thymine (Molecular Probes 
Inc., 2005). AT-rich double stranded DNA strands will enhance the blue fluorescence 
considerably. The staining procedure for Hoechst is to add 530 uL of Hoechst to 270 uL 
of cellular growth medium and incubate the cell cultures for 30 minutes. After 
Figure 5. Mitotracker Red. Live HCT116 cells stained with Mitotracker Red and 
viewed under the laser confocal microscope at 100x magnification. The Mitotracker 
Red labels the mitochondria of the cell.  
10 um 
Transmitted Image 
Merged Mitotracker Red 
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incubation, the cells should be washed with cellular medium and then once with HBSS 
before imaging. 
CELL DEATH WITH TIDOL, LUCIFERIN, AND ATP 
 One of the first experiments that were carried out was designed to test the effects 
that nanoparticles and nanoconjugates have on the cellular cultures. An 8-well plate was 
designed (see Table 2) to have two wells (well 5 and well 6) that would test if our 
nanoconjugate would be activated and cause cell death in two concentrations. The 
remaining wells were used as controls to determine if individual components of our 
active nanoconjugate would have any effect on the cells.  
Our first attempt at an experiment to combine the TiDoL, Luciferin (Gold 
Biotechnologies, St. Louis, MO), and ATP (Sigma-Aldrich, St. Louis, MO) to test our 
hypothesis that it will cause the HCT116 cells to become apoptotic was very successful. 
The well contents were added to the cells as described in Table 2 except for the Luciferin 
which was added last. After the 60 uL of Luciferin was added to the cells, in two doses of 
30 uL for 30 minutes each, the 8-well plate was observed under the light microscope. A 
drastic change in appearance was observed for some of the conditions after just one hour. 
The plate had the wells replaced with cell growth medium and was left overnight in the 
incubator. On the next day the cells were stained with WGA and Mitotracker Red, and 
then observed under the laser confocal microscope.  
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1.  
202 uL HBSS 
98 uL PBS 
2. 
202 uL HBSS 
22 uL PBS 
8 uL Luciferase 
8 uL ATP 
60 uL Luciferin 
(30+30) 
3. 
202 uL HBSS 
30 uL NP(TiO2-DC) 
8 uL Luciferase 
8 uL ATP 
60 uL Luciferin 
(30+30) 
 
4. 
202 uL HBSS 
68 uL PBS 
30 uL NP (TiDoL) 
5. 
202 uL HBSS 
30 uL NP (TiDoL) 
8 uL ATP 
60 uL Luciferin 
(30+30) 
6.  
202 uL HBSS 
30 uL NP (TiDoL – 
partial conjugation) 
8 uL ATP 
60 uL Luciferin 
(30+30) 
 
7. 
202 uL HBSS 
30 uL PBS 
8 uL ATP 
60 uL Luciferin 
(30+30) 
8. 
202 uL HBSS 
68 uL PBS 
30 uL NP (TiDoL – 
partial conjugation) 
 
Table 2. TiDoL Experiment Design. Diagram of the 8-well plate of HCT116 cells and 
how they were treated. 
 
 The control wells, wells 1, 2, 3, 4, 7, and 8 did not cause cells to undergo 
apoptosis (Appendix G). This means the controls did not harm the cells when they were 
on their own enough to cause the cells to die. The cells in the control wells had 
maintained their elongated epithelial cell shape. The WGA stained the cellular membrane 
and Golgi apparatus a fluorescent green, and the Mitotracker Red stained the cell 
mitochondria a fluorescent red, leaving an empty dark opening where the nucleus is 
located. 
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The experimental wells, well 5 and well 6, did cause the cells to undergo 
apoptosis. In well 5 we had the fully conjugated nanoparticle TiDoL, where in the 
process of conjugation we had a 250-fold excess of Dopac in comparison to Luciferase. 
When well 5 was examined under the laser confocal microscope, it was evident that the 
cells had significantly changed their configuration from the healthy elongated epithelial 
Figure 6. Well 4. The HCT116 cells in well 4 were used as a control, and treated with 
30 uL of fully conjugated TiDoL. WGA was used to stain the cellular membrane and 
Golgi apparatus (indicated by arrows) green, and Mitotracker Red was used to stain 
the mitochondria a fluorescent red. The cells in this photograph represent what a 
typical healthy HCT116 cell would look like when stained and observed under the 
laser confocal microscope at 100x magnification. The bottom right square is a layered 
view of the WGA and Mitotracker Red staining of the HCT116 cells. 
10 um WGA 
Mitotracker Red Merged 
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cell shape (see Appendix H) to a smaller and more circular shape. The WGA stains the 
cellular membrane and the Golgi apparatus as a bright green spot near the nucleus, and 
when the cells die the Golgi stain disappears. The cells also had changed their inner 
cellular structure as visible by the Mitotracker Red staining. The Mitotracker Red stain is 
positively charged and accumulates in the mitochondria when HCT116 cells are alive and 
healthy, and leaves the area of the nucleus unstained appearing black in images. When 
the HCT116 cells undergo a programmed cell death, apoptosis, the membrane potential 
and permeability of mitochondria disappear and the nuclear membrane changes allowing 
the Mitotracker Red dye to enter the nucleus and fluorescent red can be visible 
throughout the cell. Also visible is internucleosomal DNA fragmentation giving the 
insides of the cells a frothy appearance. The formation of membrane enclosed apoptotic 
bodies was visible under the confocal microscope, and is a consistent with apoptosis.  
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 This experiment was continued by staining well 5 with Hoechst dye to visualize 
what happens to the nuclear material in the dead cells. Once well 5 was stained for 30 
minutes with 30 uL of Hoechst, the well was imaged with the chameleon laser under the 
Figure 7. Well 5. The HCT116 cells in well 5 viewed under the laser confocal 
microscope at 100x magnification after treatment with TiDoL nanoparticle conjugates 
in high concentration, ATP, and activated with two doses of Luciferin. All of the 
HCT116 cells imaged here have visibly changed shape and inner configuration during 
apoptosis when compared to healthy HCT116 cells from other wells (not pictured). 
There is no longer a non-staining area where the nucleus is. Also visible is the 
formation of a membrane enclosed apoptotic body (indicated by arrow).  
10 um 
WGA 
Mitotracker Red 
Transmitted Image 
Merged 
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confocal microscope. With the images taken, we can confirm that there is nuclear 
material throughout the cell and in apoptotic bodies, as the cells undergo apoptosis.  
 
Figure 8: Well 5 stained with Hoechst. The HCT116 were stained with Mitotracker 
Red and Hoechst, and then viewed under the confocal microscope at 100x 
magnification. The Hoechst stains nuclear material, as seen in this image the blue stain 
is located throughout the cell and is no longer confined by the nuclear membrane, 
indicating cell death. 
 
10 um 
Mitotracker Red Hoechst 
Merged 
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In well 6 we had the nanoparticle TiDoL conjugated by only a 20-fold excess of 
Dopac compared to Luciferase. When well 6 was observed under the laser confocal 
microscope we saw cells that had changed their shape to a smaller more circular cell 
similar to those in well 5 (see Appendix I). Those same cells had other signs of apoptosis 
such as a missing Golgi apparatus, Mitotracker Red staining throughout the cell, and 
Figure 9. Well 6. The HCT116 cells in well 5 stained with WGA and Mitotracker 
Red, viewed under the laser confocal microscope at 100x magnification by after 
treatment with TiDoL nanoparticle conjugates in low concentration, ATP, and 
activated with two doses of Luciferin. The HCT116 cells have visibly changed shape 
and inner configuration (indicated by purple arrows), but also some healthy HCT116 
cells are visible (indicated by blue arrows).  
10 um WGA 
Mitotracker Red 
Transmitted Image 
 Merged 
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some apoptotic bodies. However, we also observed that some cells had not changed from 
their normal shape and looked very much like the healthy HCT116 observed in the 
controls. 
 
 Our conclusion is that the partially conjugated TiDoL as a result of only 20-fold 
excess of Dopac compared to Luciferin was not high enough. The fully conjugated 
TiDoL with 250-fold excess of Dopac compared to Luciferase as used in well 5 worked 
better because it caused all of the cells in that well to undergo apoptosis. Also of 
importance is that only the conjugated TiDoL with ATP and activated with Luciferin 
caused cell death. The control wells all showed that these chemicals in their unconjugated 
forms are not harmful to the cells.  
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CELL DEATH WITH ANTIBODY C225 
 Our previous experiment with TiDoL, ATP, and Luciferin showed that when 
these chemicals are conjugated they can produce photoactive species resulting in efficient 
ROS production and inducing programmed cell death in HCT116 cells. Our next step is 
to conjugate the TiDoL molecule to a C225 antibody that will allow for selective binding 
Figure 10. Macroscopic Photo of Cell Plate. A macroscopic photograph shows the 
color change of cellular growth medium in the experimental wells of the plate of 
HCT116 cells. The cellular growth medium is originally a pink color but changes to a 
yellow color after cells have harvested all the nutrients from it. In well 5 the growth 
medium remains a pink color because the cell cultures are dead and no longer using 
nutrients. In well 6 there is slight pink but more orange color as some cells have died, 
but a small concentration are living and using nutrients. In the remaining wells the 
growth medium has had its nutrients used up by the living cells and is therefore visibly 
yellow in color.  
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to the HCT116 colon cancer cells. The HCT116 cells used in our experiment overexpress 
EGF receptor on their cell membrane surface, and by using the C225 anti-EGFR 
monoclonal antibody we hope to target the HCT116 cells specifically (National Cancer 
Institute, 2012).  
 We began the experiment working to finding the best procedure to synthesize a 
TiDoL-C225 nanoconjugate. First, 185 uL of C225 (13.3 uM, 2 mg/mL), 10 uL of 60 
mM Dopac, and 14 uL of mixed 50 mM EDC and 50 mM NHS were combined. In 
another tube 125 uL of Luciferase (8.5 uM), 10 uL Dopac, and 16 uL of mixed 50 mM 
EDC and 50 mM NHS were combined. Both solutions were reacted overnight in the 4 
degree C refrigerator. The next day both solutions were purified with the centrifuge four 
times at 13,500 rpm for six minutes each with PBS. Both the C225 and luciferase 
solutions were concentrate to 125 uL. Then, 200 uL of 10 uM particles of TiO2 was 
added to 100 uL of Luciferase solution. This solution was divided in two and 125 uL of 
C225 solution was added to on portion of TiO2 and Luciferase solution, and a noticeable 
yellow color appeared. Then, an additional 50 uL of Dopac was added to the solution in 
the nitrogen box to shift absorption of the construct in the visible. The final concentration 
of the TiDoL-C225 solution is 4.125 uM with an excess of 0.28 uM free C225 or about 
5%. The TiDoL-C225 solution was used in various concentrations in the experimental 
wells of the 8-well HCT116 cell plate.  
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1.  
202 uL HBSS 
98 uL PBS 
2. 
202 uL HBSS 
88 uL PBS 
10 uL C225-DC 
 
3. 
202 uL HBSS 
30 uL C225-DC 
8 uL ATP 
8 uL Luciferase 
60 uL Luciferin 
(30+30) 
 
4. 
202 uL HBSS 
30 uL TiDoL-C225 
8 uL ATP 
60 uL Luciferin 
(30+30) 
5. 
202 uL HBSS 
30 uL TiDoL-C225 
8 uL ATP 
60 uL Luciferin 
(30+30) 
6.  
202 uL HBSS 
5 uL TiDoL-C225  
8 uL ATP 
60 uL Luciferin 
(30+30) 
7. 
202 uL HBSS 
8.3 uL TiDoL-C225 
8 uL ATP 
60 uL Luciferin 
(30+30) 
 
8. 
202 uL HBSS 
8.3 uL TiDoL-
C225/10 
60 uL Luciferin 
(30+30) 
Table 3. Experiment Design of Plate TiDoL-C225. A diagram of the 8-well 
plate of HCT116 cells and how they were treated in this experiment. 
 
 The Luciferin was added in two doses of 30 uL and left to incubate for 30 minutes 
each time. For some wells, after treatment with the antibody there was a noticeable 
peeling of the cells from the bottom of the well where they were previously adhered and 
subsequent folding over of this film of cells. This would make it difficult for viewing the 
cells under the confocal microscope where the optimal viewing conditions are one cell 
layer. We proceeded with the staining process immediately after reacting the cells with 
the antibody. Previously we had washed the cells after reacting them and let them 
incubate in media before staining. The immediate staining may have added additional 
stress to the cells. The wells were stained with Mitotracker Red and WGA. Then they 
were observed under the laser confocal microscope. 
We concluded that seeing the Golgi apparatus stained with WGA was a good sign 
that the HCT116 cell was alive and healthy. Normally the visible Golgi along with the 
empty space of the nucleus where Mitotracker Red does not stain are signs of a visibly 
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healthy HCT116 cell. The dead cells did not show the bright green Golgi stained with 
WGA. 
 
The C225 antibody binding to the surface of the HCT116 cells could be the 
reason for their loss of adherence to the bottom surface of the well. When the antibody 
binds to the surface it can interfere with their stickiness. We observed the loss of 
Figure 11. Well 2.  HCT116 cells viewed under the laser confocal microscope at 100x 
magnification, stained with WGA and Mitotracker Red. The cells are alive after 
treatment as seen by the visible Golgi apparatus (some examples are indicated by 
arrows) and nonstaining nuclear space. 
10 um 
WGA Transmitted 
Image 
Mitotracker 
Red 
Merged 
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adherence in wells # 3, 4, 5, 6, 7, and 8 (see Table 3). Well 1 and well 2 did not lose 
adherence.  
Wells 1, 2, and 3 were our control wells that should not have caused ROS to form. 
The purpose of these control wells was to show the effect of C225 antibody binding alone 
to the HCT116 cells does not harm the cells. To take this one step further, well 3 was 
treated with the C225 antibody to show that it will not be activated, even with two doses 
of Luciferin, without the nanoparticle TiDoL conjugated to it to create the ROS. This 
sample was also partially detached from the bottom of the well. The control wells proved 
our theory correct, as all the cells remained healthy after treatment. The cells were 
observed again after one day to confirm they were still alive, and there was even a 
noticeable amount of replication seen. 
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Wells # 4, 5, 6, 7, and 8 (see Table 3) were our experimental wells that were 
treated with TiDoL-C225 in various concentrations and should exhibit activation by 
Luciferin to create ROS and induce cell death. 
Our experiment indicated that the TiDoL-C225 was selectively binding to the 
HCT116 cells, as when Luciferin was added to the well the cells underwent programmed 
Figure 12. Well 2 After 24 Hours. HCT116 cells stained with WGA and Mitotracker 
Red are viewed under the confocal microscope at 100x magnification 24 hours after 
they were treated with C225 antibody. The cells are still alive as seen by the brightly 
green WGA staining Golgi apparatus and non-staining nucleus by Mitotracker Red. 
The cells are more confluent than the day before which is a sign of their replication 
and reaffirms that the cells are alive. 
50 um 
WGA Transmitted Image 
Mitotracker Red Merged 
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cell death even at the concentration of 2.8 uM TiDoL. The cell died faster when the 
antibody bound because we did not observe a significant change in shape of the cell. 
More apparent was that the Golgi apparatus was not staining any longer.  
 
We also observed differences with the Mitotracker Red dye in the cells that were 
dead. The Mitotracker Red dye did not always fully penetrate the nucleus. This could be 
Figure 13. Well 7. In well 7, 8.3 uL of TiDoL-C225 was added to the HCT116 and 
activated with Luciferin. The WGA staining the membrane green, however no Golgi is 
visible. The Mitotracker Red dye has spread throughout the cell and there is no longer 
a nonstaining area where the nucleus was. These cells have undergone controlled cell 
death. The cells were viewed with a confocal microscope at 100x magnification. 
10 um 
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because of the change in the protocol of staining as we did not allow the cells enough 
time to incubate and undergo the beginning steps of apoptosis before observing them as 
we had to stain the cells immediately after the addition of Luciferin. With more time, we 
believe the Mitotracker Red would have stained the whole dead cell as we have 
previously seen. We observed the cells again the next day to confirm that the Mitotracker 
Red had indeed spread and there was no longer an area that was not stained.  
  
Figure 14. Well 7 After 24 Hours. This is the same well 7 as in Figure 13 viewed 
under the confocal microscope after 24 hours at 100x magnification. This image 
confirms the cells have undergone apoptosis.  
10 um 
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 The concentrations of TiDoL-C225 had an impact on the amount of cells that 
were killed by the treatment. In the least-concentrated well 8 the HCT116 cells were 
treated with 0.83 uL of TiDoL-C225 (2.8 nM TiDoL concentration) nanoconjugate. 
These cells had some undergoing apoptosis, however we were also able to find some 
Figure 15. Well 8. The HCT116 cells in well 8 were treated with the lowest dose of 
TiDoL-C225 nanoconjugate. The cells were stained with WGA and Mitotracker Red 
and imaged under the confocal microscope at 100x magnification. Some of the cells 
responded to the treatment, however some living cells are also apparent. The dose of 
TiDoL-C225 was not large enough to effectively cause all cells to begin programmed 
cell death.  
10 um 
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living cells. This result indicates that a low dose of TiDoL-C225 is not as effective. Well 
6 was treated with our second lowest dose of 5 uL of TiDoL-C225 (100 nM TiDoL 
concentration), and this dose appeared to work effectively at killing the HCT116 cells. 
CELLS UNDERGOING APOPTOSIS IN REAL TIME 
 In the previous experiments I was treating the HCT116 cells with the TiDoL or 
TiDoL-C225 nanoconjugate and imaging them after they had started to undergo the 
process of apoptosis or even once they were dead. I wanted to observe the HCT116 cells 
immediately after we activated the ROS producing reaction and throughout apoptosis. I 
decided to image the HCT116 cells under the confocal microscope where the software is 
capable of creating a time series of images and combining them into a video clip. This 
allows us to view the HCT116 cells from the moment the reaction begins, throughout the 
process of apoptosis, and even after cell death.  
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Figure 16. Frames from HCT116 Cell Movie of Apoptosis. The HCT116 cells were 
treated with TiDoL and ATP in the first frame, and they appeared normal. As soon as 
the cells were treated with Luciferin in the second frame they began to shrink and 
shift. In the third frame apoptotic bodies begin to form as membrane enclosed vesicles 
that are being filled with the contents of the cells. The cells have a drastic change in 
appearance from the first frame where they appeared healthy, and now have 
condensed chromatin in the nucleus and a frothy appearance in the cytoplasm. 
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IN VIVO STUDY WITH MICE 
 An in vivo study with mice is in preparation at University of Chicago. There will 
be 16 nude mice in the experiment. All of the mice will receive an HCT116 injection on 
both flanks (3 million cells/flank/mouse) to introduce a xerograph tumor. The 
nanoparticle agents that will be used are Luciferin, TiO2, C225 antibody, TiDoL, and 
TiDoL-C225. Luciferin will be used in solution of 15 mg/mL in PBS, where 10uL/g of 
body weight will be administered to the mouse with an intra-peritoneal injection. There 
will be four groups of mice. Group A will include six mice that will receive a TiDoL 
injection into each of the tumors; three will be with Luciferin and three will be without 
Luciferin injected intra-peritoneally. Group B will also include six mice that will receive 
a TiDoL-C225 injection into each of the tumors; three will be with Luciferin and three 
will be without Luciferin injected intra-peritoneally. Group C will include two mice with 
only TiO2 injected into each tumor. Group D will include two mice that will have both 
tumors injected only with C225 antibody. Measurements of the tumor xenographt size 
will be taken every Monday, Wednesday, and Friday for a month. After one month’s 
time, the mice will be sacrificed, histological analysis of the tumor, liver, and kidney will 
be carried out, and frozen sections of the tumor will be made.  
 This in vivo study hopes to show that the therapy will be successful in shrinking 
the tumor size, and selectively targeting only the tumor cells without harming the other 
cells of the organism. If this study is successful it will be the first step to making this 
therapy an improved treatment for cancer. 
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DISCUSSION 
 
 We used TiO2 nanoparticles with Luciferase conjugated to them, and these 
nanoparticles are activated by ATP overproduced by the cancer cells to create reactive 
oxygen species (ROS) and cause apoptosis of the cancer cells. This therapy has 
tremendous potential as a treatment and possible cure for cancer with continued research 
and experimentation.  
The background information on the topic of PDT varies because there are sources 
regarding the original methods of PDT that emerged in the late 1970s. Only recently have 
scientists began to experiment with bioluminescence and PDT and most of this research 
began in the late 2000’s and is currently continuing (Widder, 2010). The even newer 
methods with Luciferase and especially using nanotechnology are currently being carried 
out by a limited number of groups and has resulted in very few publications in the past 
year or two (Zheng et al., 2012 and Zhao et al., 2013). I was surprised to find that 
experiments to further develop PDT beyond its limitations due to poor light penetration 
have only recently become a hot topic of study. After reading the literature on the topic 
there seems to be much potential for growth, and many studies have shown very 
promising results. Since it is very current and many different methods are being 
experimented with at this time I would say it is difficult to name one distinguished expert, 
but rather every experimenter seems to be an expert in their particular scope of 
experimentation.  
The journal articles I have found on PDT have varied from background 
information on the process of PDT to newer experiments involving PDT. Zhao et al. has 
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been experimenting with a bioluminescent microcapsule of Luciferin that can be used for 
PDT to prevent the proliferation of tumor cells (2013). It seems that many researchers 
have seen the potential in PDT as a therapy for cancer and the next obstacle to overcome 
is to increase the depth to which PDT can be applied. Articles including luciferase 
narrowed my search, and were frequently more current experiments focused on 
bioluminescence and PDT. I found that the more recent articles that described 
experimentation with bioluminescence and PDT to be the most helpful because they are 
the most similar to the research I am doing. The background information I found in my 
earlier searches was definitely helpful in understanding PDT and its limitations regarding 
its effectiveness for deep tissues. The Zhao et al., 2013 article from Chemistry – A 
European Journal described the process of PDT but also incorporated a bioluminescence 
portion with their use of Luciferase in microcapsules to deliver it to deeper tissues. This 
article was informative on every level, in comparison to the Macdonald & Dougherty, 
2001 article that was just a basic summary of PDT from beginning up to the advances in 
2001.  
The nanoparticle field of PDT has not been explored and so many of the articles 
in my literature review have previous experiments with larger biological molecules. The 
nanoparticles conjugates we created in my research are a new method of PDT, and 
hopefully prove a more successful treatment to penetrate tissue and reach the deep tissue 
tumor cells. PDT is fairly new and many experiments are currently being undertaken to 
see what methods will have the most potential for advancement. The research that we 
conducted has a great potential for advancing PDT with an incorporation of 
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bioluminescence with nanoparticles, and may even pave the way for a very effective 
treatment if not eventual cure for cancer. 
 This study demonstrates that we have improved upon the conventional method of 
PDT by introducing a vehicle to target tumors in which bioluminescent nanoparticles 
were conjugated to cell specific antibodies that when activated by ATP will create ROS 
to induce apoptosis of tumor cells. The major findings were; the optimal nanoconjugate 
synthesis protocol to make TiDoL and TiDoL-C225 (i), the nanoconjugate is able to bind 
specifically to caner cells when bound to a corresponding antibody (ii), the optimal cell 
staining protocols (iii), that the TiDoL nanoconjugate was only active and effective at 
killing tumor cells once activated by Luciferin (iv), that the TiDoL-C225 nanoconjugate 
increases the efficacy of binding to tumor cells and causes a faster reaction in the cells to 
begin apoptosis (v), and finally that our PDT technique allowed us to watch the tumor 
cells beginning to undergo apoptosis in less than five minutes after the Luciferin was 
added to activate the reaction (vi).  
Optimizing Nanoconjugate Synthesis 
 After investigating to find the optimum synthetic parameters of the nanoconjugate 
that maximize the light output and the formation of ROS in vitro we were able to 
establish a protocol that produced the desired results. We manipulated the size and shape 
of TiO2 nanoparticles in order to control their electronic and chemical properties 
(Saponjic et al., 2005). We modified TiO2 nanoparticles with Dopac, a dopamine 
derivative, to harvest visible light and promote spatial separation of charge to make ROS 
superoxide anions (Dimitrijevic, Rozhkova, & Rajh, 2009). The TiO2-Dopac conjugate 
  52 
allowed for strong binding of Luciferase to the surface of the TiO2. The next step was to 
add a targeting molecule. Our choice was anti-EGFR monoclonal antibody C225 that  
 
corresponds well to the overexpression of EGF receptors on the surface of the HCT116 
colon cancer cells. This final species of TiDoL-C225 proved to be highly effective in 
carrying out the series of redox reactions to cause the cancer cells to undergo apoptosis.  
Western Blots 
 Western blots were performed in order to determine the efficacy of binding of 
C225 to EGFR overexpressed on the surface of HCT116 colon cancer cells. We are 
experimenting with HCT116 cells that had been treated with C225 and agonist EGF. The 
blots were probed with a variety of antibodies: P-AKT, P-ErbB2 (P-Neu), P-ERK, and P-
EGFR. The blots showed good inhibition with C225 at various concentrations of EGF 
Figure 17. TiO2 modified with dopamine. This figure shows a TiO2 nanoparticle 
with a Dopamine particle bound to the surface. The Dopamine allows for a greater 
separation of localized charge that enable the production of ROS. (Figure taken from 
Dimitrijevic, Rozhkova, & Rajh, 2009). 
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and suggest efficient binding. These results are as expected since the HCT116 have an 
overexpression of EGF receptors on their cell surface.  
Optimize Cellular Staining 
 Cellular staining techniques were optimized for our experimental conditions 
starting from the distributor protocols and by changing the concentration of the dyes. The 
cellular staining was carried out with live HCT116 cells, and we had to take care not to 
damage the cells with the stains. None of the HCT116 cells were fixed in formalin before 
staining, as we wanted to observe the process of cell death under the confocal 
microscope. The WGA stain was used to label the cell membrane and Golgi apparatus 
with a fluorescent green color (Alexa 488). Mitosox Red was used to label superoxide 
species generated by the mitochondria under stress, but was not sufficiently visible under 
the confocal microscope under non-stressful conditions. The Mitotracker Red was the 
preferred dye used to stain the mitochondria’s many sulfhydryl groups and was much 
more visible under the confocal microscope. The nucleus of the HCT116 cells was 
imaged by Hoechst stain which binds to the minor groove of DNA, and can indicate 
programmed cell death through the appearance of a pyknotic condensed nucleus. 
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Cell Death with TiDoL 
 The first experiment we carried out was to confirm whether our idea of a 
nanoconjugate comprised of TiO2, Dopac, and Luciferase would be successful in forming 
ROS once activated by Luciferin and ATP. We immediately saw once Luciferin was 
Figure 18. HCT116 cells stained with WGA and Mitotracker Red. This image 
shows live HCT116 cells viewed under the confocal laser microscope at 200x 
magnification, after being stained with WGA and Mitotracker Red. The green color 
comes from WGA that stains the membrane and Golgi apparatus (indicated by 
arrows), and the red color is from Mitotracker Red, which stains the mitochondria. 
10 um 
Merged 
WGA 
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added that we had caused a change in the cell conformation, and the cells had begun to 
undergo cell death. We experimented with two conjugation protocols of TiDoL to make 
two conjugates that varied in the degree of conjugation, TiDoL-1 and TiDoL-2. The 
TiDoL-1 obtained by conjugation with 250-fold excess linking agent Dopac was used in 
wells # 4, 5, and 7 (see Table 2) and proved to be better conjugated than the TiDoL-2 
obtained by using a 20-fold excess of Dopac that was used in well 6 and well 8. We know 
that the TiDoL-1 obtained by the first protocol was better conjugated because for the 
same concentration of TiDoL-2 applied to the HCT116 we saw that all of the cells were 
affected by Luciferin and had signs of apoptosis. While those cells treated with TiDoL-2 
were only partially affected. Therefore we conclude that the second protocol lead to a less 
conjugated TiDoL-2 where some cells were dying, but also some were alive. We 
continued the study by making the TiDoL-1 following the procedure that gave us the 
higher conjugated TiDoL. The HCT116 cells of the experiment were stained the next day 
with WGA and Mitotracker, and then observed under the confocal microscope. Another 
important aspect of this experiment was that we established the control wells to show that 
the components of the reaction do not harm the cells unless the TiDoL is completely 
conjugated, and further, activated by ATP and Luciferin. In well 1 we did a standard 
control of HBSS and PBS, the mediums that we would be reacting the cells in. The cells 
in well 1 were completely alive and looked healthy when observed under the confocal 
microscope. The next well, well 2, was designed to include all items in the reaction 
except the conjugated nanoparticles. Well 2 had HBSS, PBS, Luciferase, ATP, and 
Luciferin. When this well was reacted we saw that the cells remained healthy, this is  
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presumably because the nanoconjugate was not there to create the light in situ that would 
then form the ROS species. A similar setup was used in well 3 where this time we 
included TiO2-Dopac functionalized nanoparticles with free Luciferase, ATP, and 
Luciferin. Although this well had all the elements of the reaction, because the TiO2-
Figure 19. Well 3. The HCT116 cells were treated with TiO2-Dopac, free Luciferase, 
ATP, and Luciferin. The cells were stained with WGA and Mitotracker Red. The 
treatment included all elements of the reaction, however the reaction was not able to 
produce ROS because the Luciferase was not bound to the nanonconjugate. The cells 
were observed with a bright Golgi apparatus stain from WGA, open nonstaining area 
for the nucleus from Mitotracker Red, and continuous cell membrane of an elongated 
shape. The cells were viewed with the confocal microscope with a 20x objective.  
 
50 um 
WGA Transmitted Image 
Mitotracker Red Merged 
  57 
Dopac and Luciferin were not conjugated into TiDoL, they were unable to carry out the 
reaction form the ROS and the cells remained unharmed (Appendix G).  
In well 4 we included TiDoL nanoparticles alone and showed that the 
nanoconjugate alone does not harm the epithelial HCT116 cells. Another point that 
should be emphasized is that none of these molecules by themselves have proved to be 
damaging to the HCT116 cells, they are only destructive if the reaction is carried out 
Well 5 Well 6 Well 4 
Figure 20. Wells 4, 5, and 6. The HCT116 cells were stained with WGA (upper left 
quadrant) and Mitotracker Red (lower left quadrant) imaged under the confocal microscope 
at 20x objective, and the bottom row with an additional 100x magnification. This figure 
compares the effectiveness of each treatment by showing how cells in well 5 are all 
completely dead; in well 6 are a combination of dead and some live cells, and in well 4 
where all the cells are healthy. The grayscale is the transmitted image in the upper right 
quadrant of the 20x row, and the lower right quadrant is the merged image. 
20
x 
10
0x
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completely as the nanoconjugate TiDoL is activated by ATP and Luciferin. We 
concluded that the fully conjugated TiDoL-1, as in well 5, was effective in carrying out 
the ROS reaction and causing the HCT116 cells to undergo apoptosis.  
 
Cell Death with TiDoL-C225 
 Now that our previous experiment confirmed the effectiveness of TiDoL to create 
ROS once activated by Luciferin and ATP, we hoped that including the C225 anti-EGFR 
monoclonal antibody in the conjugate will allow us to target the HCT116 exclusively for 
apoptosis. This experiment concentrated on the ability of our TiDoL-C225 nanoconjugate 
to selectively bind to HCT116 tumor cells with the inclusion of the corresponding 
antibody. HCT116 colon cancer cells have an overexpression of EGF receptors on their 
membrane that can bind to C225 antibody (National Cancer Institute, 2012). The set up 
of the experiment was kept similar to the previous TiDoL experiment including the 
various concentrations of TiDoL-C225 used (see Table 3). Wells # 1, 2, and 3 were our 
control wells for the experiment. In well 1 we included HBSS and PBS to show the effect 
of the medium we will have when imaging the cells. The cells were not affected by either 
solution and appeared normal when viewed under the confocal microscope. In well 2 we 
added the C225 antibody conjugated to Dopac. The cells were not stressed by the C225, 
they were stained with Mitotracker Red and WGA and appeared normal when viewed 
under the confocal microscope. The WGA stained the cell membrane and Golgi 
apparatus, and the Mitotracker was confined to the mitochondria and the cells showed a 
dark nonstaining area where the nucleus is. In well 3 we had the C225-DC antibody and 
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free Luciferase, and then ATP and Luciferin. The C225-DC was not activated because it 
was not conjugated to Luciferase and TiO2. The cells were also stained with Mitotracker 
Red and WGA and when observed under the confocal microscope they were alive. We 
checked on them the next day and confirmed that the cells were still alive and the 
reaction had not caused the cells to undergo apoptosis. This is of crucial importance for 
developing a therapy because it means the components of the reaction individually will 
not harm the cells of the organism.  
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 The remaining wells # 4, 5, 6, 7, and 8 (see Table 3) were used to experiment with 
the concentration of TiDoL-C225 necessary to carry out the reaction. Well 5 had the 
highest concentration of TiDoL-C225 of 30 uL (600 nM TiDoL concentration). The 
HCT116 cells were stained with Mitotracker Red and WGA and when viewed under the 
confocal microscope appeared dead. The Mitotracker had dispersed throughout the cell 
and there was no longer a nonstaining area where the space of the nucleus is located. The 
WGA showed the cell membrane, but the Golgi apparatus was no longer visible. The 
Figure 21. Well 2. The HCT116 cells stained with Mitotracker and WGA and treated 
with C225-DC remain alive. There is a visible Golgi apparatus (indicated by arrows), 
and dark nonstaining area where the nucleus is located. The cells were viewed with the 
confocal microscope at 100x magnification. 
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cells in well 5 were observed again the next day, and there did not appear to be any living 
cells, only the cellular membranes with whatever remains of the cell inside, confirming 
that the reaction was successful in causing the cells to undergo apoptosis. In well 7 we 
decreased the amount of TiDoL-C225 added to 8.3 uL (140 nM TiDoL concentration). 
Well 7 was viewed under the confocal microscope and the cells all appeared dead. The 
Golgi apparatus had disappeared, and the Mitotracker Red stain had spread throughout 
the cell. The next day the cells were all still dead, none had recovered. 
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Well 6 had 5 uL of TiDoL-C225 (concentration of 100nM TiDoL) added to the 
HCT116 cells. When the TiDoL-C225 was reacted with Luciferin and ATP we were 
excited to find that all of the cells had been killed even with this lower concentration as 
observed with the confocal microscope. Finally, in well 8 we added the least amount of 
Figure 22. Well 7. The HCT116 cells were stained with WGA and Mitotracker Red 
and treated with 8.3 uL of TiDoL-C225. The TiDoL-C225 was then activated with 
ATP and Luciferin to cause the all of the cells to undergo apoptosis. The Mitotracker 
Red stain has spread throughout the entire area of the cell and the Golgi apparatus is 
no longer stained by the WGA. The cells were viewed with the confocal microscope at 
100x magnification. 
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only 0.83 uL TiDoL-C225 (16.7 nM TiDoL concentration) and activated It with Luciferin 
and ATP. The HCT116 cells were stained with WGA and Mitotracker Red and viewed 
with the confocal microscope. The majority of the HCT116 cells had been killed by the 
reaction, however there were some cells that had not been affected. By counting the cells 
we can say that less than 5% of the HCT116 cells had survived when we observed well 8 
the following day. We can conclude that this amount of TiDoL-C225 was not sufficient 
to create enough ROS to cause all of the cells to undergo apoptosis, however it was 
approximately 95% affective. For our therapy we will use a higher concentration to 
ensure that 100% of the cells will undergo controlled cell death.  
 Well 4 was omitted because it was ineffectively stained with WGA and Mitosox 
Red, which was not visible under the confocal microscope and so we could not record 
results for well 4.  
Cells Undergoing Apoptosis in Real Time 
 The movies we have made by taking time series photographs with the confocal 
microscope have allowed us to see continuous effects of our therapy on the cellular level. 
We were able to focus on a few HCT116 cells and observe their reactions to the therapy 
in real time. The ability to watch the cells go through the steps of apoptosis has been 
exciting. We were able to visualize the cells changing configuration, from their normal 
elongated epithelial shape to a rounder and smaller cell at the beginning stages of 
apoptosis. Next we can see the contents of the cell changing and becoming frothy. Also 
the chromatin in the nucleus condenses and becomes darker. At the final stage we can 
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observe the cells creating small membrane enclosed buds called apoptotic bodies, and 
filling them with the degraded cell contents (Catchpoole & Stewart, 1995). 
 
 
Further, if the HCT116 cells are stained with cellular dyes before treatment, they 
can be visualized with the laser confocal microscope as they change throughout the 
treatment. A complication in this technique is that some cellular stains can be bleached 
by the laser excitation, and lose their fluorescence with time. To avoid bleaching, we 
used Alizarine ink, a stain that forms a fluorescent complex with TiDoL, to the 
Figure 23. Freeze frame from movie of HCT116 cells undergoing apoptosis. The 
HCT116 cells are viewed under the confocal microscope while they are being treated 
with the nanoconjugate therapy. These cells have already begun to shrink but remain 
in contact by only the thin actin projections connecting them. The appearance of the 
inner contents of the cell is frothy, and the nuclear matter is condensed. The cells have 
formed apoptotic bodies (indicated by arrows) and are filling them with their cellular 
contents. 
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nanoconjugate and observed the HCT116 cells fluoresce a red color when the TiDoL was 
activated (Thurn et al., 2009).  
 
The continuous monitoring of cell changes in real time during therapy is novel 
and exciting. We were able to experiment with doses and concentrations and see if the 
cells respond faster and die quicker when the nanoconjugates absorbed more of the 
Luciferase produced light. The therapy with TiDoL-C225 proved to be much quicker at 
Figure 24. Alizarine Ink. The HCT116 were treated with TiDoL-C225 bound to 
Alizarine ink and viewed at 63x magnification under the confocal microscope. The 
Alizarine ink fluoresces red and indicates that the TiDoL-C225-Alizarine has more 
efficient binding to the HCT116 cell surface especially in comparison to the TiDoL-
Alizarine without C225 antibody at equal concentrations. The TiDoL-Alizarine is 
dispersed in solution and shows less red fluorescence on the surface of the cells without 
the targeting C225 antibody. 
TiDoL-C225-Alizarine TiDoL-Alizarine 
Free Alizarine Free Alizarine Transmitted Image Transmitted Image 
Alizarine  Alizarine Merged Merged 
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causing apoptosis than the same concentration of TiDoL nanoconjugate alone. This is 
another indication that our therapy is effective at binding specifically to HCT116 cells 
and causing them to undergo apoptosis. 
Future Significance 
 The new PDT technique we have developed can be used as a way to image deep 
tissue tumors or even as a treatment of cancer. The nanoconjugates can be used for 
minimally invasive therapies, such as tracking the movement of therapeutic agents to 
their specific targets on a cellular scale resolution (Rajh et al., 2014). The nanoconjugates 
can be adapted with an imaging agent and used as a contrast for cell imaging with SERS, 
MRI, PET, and ultrasound (Hurst et al., 2011). In combination with the cell imaging, the 
nanoconjugate can be monitored in the targeted tissue and used for drug delivery if 
activated once at the targeted tissue.  
 The PDT therapy we developed has an advantage that it only binds to and induces 
apoptosis in tumor cells. This therapy can be expanded to an approach for early detection 
of these cancer cells, and when detected can also kill them. This eliminates the cancer 
cells before they continue their irregular replications and form tumors, thus putting a stop 
to cancer before it progresses to a later stage of the cancer.  
 Furthermore, our TiDoL-C225 nanoconjugate is specified for the HCT116 colon 
cancer cells because of the anti-EGFR monoclonal antibody we conjugated it to, however 
by changing the type of antibody in the conjugate we have opened the door to treating 
many types of cancers and diseases that express unique receptors on their surface. The 
TiDoL molecule can be conjugated to a number of cell specific antibodies that will bind 
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and activate those cells to undergo apoptosis. The new PDT we have developed is 
incredibly dynamic and has potential to not only be used as a therapy for one cancer, but 
have a much larger impact on the treatment of a multitude of cancers.  
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APPENDIX 
 
 
 
Appendix A. Zetasizer 
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Appendix B. Spectrophotometer 
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Appendix C. Confocal Laser Microscope 
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Appendix D. Optical Inverted Microscope and Camera 
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Appendix E. Biosafety Cabinet 
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Appendix F. Incubator 
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Appendix G. Control Wells 2, 3, and 8. These wells from the experiment in Table 2 
are important in establishing that the individual components of the therapy do not 
harm the cell. Well 2: all components except TiDoL, Well 3: All components with 
TiO2-DC, Well 8: TiDoL without Luciferase, Luciferin and ATP. The therapy is only 
effective if Luciferin and ATP activate the conjugated TiDoL. The HCT116 cells were 
stained with WGA (upper left quadrant) and Mitotracker Red (bottom left quadrant).  
The green color comes from WGA that stains the membrane and Golgi apparatus, and 
the red color is from Mitotracker Red, which stains the mitochondria. The grayscale 
upper right quadrants are the transmitted image and the bottom right quadrant is the 
merged image. The top row of wells are viewed at 20x magnification and the bottom 
row are the same wells viewed at 100x magnification with the laser confocal 
microscope. 
Well 2 Well 3 Well 8 
20
x 
10
0x
 
  75 
 
 
Appendix H. Healthy HCT116 Cells in 3D Labeled with WGA and Mitotracker Red 
The WGA stains the cell membrane and Golgi apparatus green and the Mitotracker Red 
stains the mitochondria red. The 3D image was made by imaging a z-stack of images of 
the cells on the laser confocal microscope. 
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Appendix I. Dead HCT116 Cells in 3D Labeled with WGA and Mitotracker Red 
The WGA stains the cell membrane and Golgi apparatus green and the Mitotracker Red 
stains the mitochondria red. The 3D image was made by imaging a z-stack of images of 
the cells on the laser confocal microscope. 
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